John F Dipersio MD

Oncology•Saint Louis, MO

Hematologic Oncology

Division Chief, Oncologist

Join to View Full Profile

4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 314-454-8304
Fax+1 314-454-5902

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1985
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1980 - 1984
University of Rochester School of Medicine and DentistryClass of 1980

Certifications & Licensure

CA State Medical License 1984 - Present
IL State Medical License 2021 - 2026
MO State Medical License 1994 - 2026
NY State Medical License 1990 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Legacy Award Leukemia and Lymphoma Society of America, 2016
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Fellow (FACP) American College of Physicians, 2012
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
St. Louis Magazine: Top Doctors Castle Connolly, 2001
Elected Member The American Society for Clinical Investigation, 1996
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Start of enrollment: 1998 Nov 01
Completed
Phase 1, Phase 2
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Start of enrollment: 2004 Apr 01
Completed
Phase 2
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Start of enrollment: 2004 May 01
Completed
Phase 1, Phase 2
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation Start of enrollment: 2005 Oct 01
Completed
Early Phase 1
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) Start of enrollment: 2007 Jul 01
Completed
Phase 2
CC-4047 (Pomalidomide) for Graft vs. Host Disease Start of enrollment: 2009 Feb 01
Completed
Phase 2
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Start of enrollment: 2009 Jan 01
Completed
Phase 1, Phase 2
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Start of enrollment: 2010 Oct 01
Completed
Phase 1
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
ACTIVE_NOT_RECRUITING
PHASE2
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies Start of enrollment: 2009 Aug 01
Completed
Phase 2
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 1
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant Start of enrollment: 2010 Apr 29
Completed
Phase 1
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases Start of enrollment: 2011 Sep 01
Completed
Phase 2
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Start of enrollment: 2012 Apr 01
Completed
Phase 1, Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Jun 09
Terminated
Phase 1, Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma Start of enrollment: 2015 Dec 01
Withdrawn
Early Phase 1
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Start of enrollment: 2020 Feb 17
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2025-03-27
Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study.
Matthew J Frigault, Richard T Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah
Blood. 2025-03-16
Clonal Hematopoiesis Landscape in Frequent Blood Donors.
Darja Karpova, Hector Huerga Encabo Dr, Elisa Donato, Silvia Calderazzo, Michael Scherer
Blood. 2025-03-11

Journal Articles

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published Data
Francesca Ferraro, Peter Westervelt, John F Dipersio, Armin Ghobadi, Leukemia Research
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and G...
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123_CD3 Bispecific Dart¬ Molecule, in Patients with ...
John F. DiPersio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Authored Content

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataAugust 2018

Press Mentions

$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024
Itacitinib Helps Prevent Graft Versus Host Disease in Stem Cell Transplant RecipientsDecember 10th, 2024
HMN 2024: New Drug Tested to Reduce Side Effect of ‘Half-Matched’ Stem Cell TransplantsDecember 6th, 2024
Join now to see all

Grant Support

Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyWASHINGTON UNIVERSITY2012–2027
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological MalignanciesWASHINGTON UNIVERSITY2017–2025
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological MalignanciesWASHINGTON UNIVERSITY2017–2025
Targeting Aml-Stromal InteractionsNational Cancer Institute2011–2012
Genomics Of Acute Myelogenous Leukemia (Aml): Relapse And Resistance FactorsNational Cancer Institute2008–2012
RES Proj 4: PET Imaging Of GVHD &Gvl Modulation Using Genetically-Modified...National Cancer Institute2007–2011
Targeting The Cxcr4-Sdf1 Axis As Therapy For Relapsed/Refractory AMLNational Cancer Institute2009–2010
Optimizing Allogeneic Transplantation Using CXCR4 BlockadeNational Cancer Institute2009–2010
DLI Using Genetically Modified T Cells: Phase 1 TrialNational Cancer Institute2004–2005
Genetic Manipulation Of T Cells--Preclinical ModelsNational Cancer Institute2001–2005
Progenitor Mobilization In Breast CancerNational Cancer Institute1994–1996
Progenitor Mobilization In Breast CancerNational Cancer Institute1993
The NA+/H+ Exchanger In Human Granulocytic CellsNational Institute Of General Medical Sciences1990–1991